Genelux GNLX
NASDAQ GNLX
$1.98 -0.09 (-4.35%)
At close: Oct 22, 2026 · 4:00 PM EDT

Genelux (GNLX) EBITDA Margin (2022 - 2024)

Updated

Genelux's EBITDA Margin was -412125.00% in FY2025, down 18862.50 percentage points from -393262.50% in FY2024.

Analysis

Genelux (GNLX) EBITDA Margin (2022 - 2024) Analysis & Trends

From FY2022 onward, Genelux has reported EBITDA Margin for 4 years.

  • EBITDA Margin has now declined for three consecutive years, with a three-year change of -412102.77 percentage points (FY2022 to FY2025).
  • Per Business Quant data, EBITDA Margin in earlier years was -393262.50% in FY2024 (-379341.32 pp), -13921.18% in FY2023 (-13898.95 pp) and -22.23% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 32.68%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 49.01%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 6.02%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 33.11%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -124.26%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 39.16%
10 Genelux 88.08 Mn 26.36 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -100,387.50%
Mar 31, 2023 -3,339.41%
Dec 31, 2022 -4,475.00%
API Access

Genelux EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GNLX&period=max&api_key=YOUR_API_KEY